Detalhe da pesquisa
1.
Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 402(10414): 1773-1785, 2023 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37858323
2.
Randomised, placebo-controlled, phase 3 trial of the effect of the omega-3 polyunsaturated fatty acid eicosapentaenoic acid (EPA) on colorectal cancer recurrence and survival after surgery for resectable liver metastases: EPA for Metastasis Trial 2 (EMT2) study protocol.
BMJ Open
; 13(11): e077427, 2023 11 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38030258
3.
Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care.
Trials
; 23(1): 552, 2022 Jul 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35804433
4.
Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer: The GO2 Phase 3 Randomized Clinical Trial.
JAMA Oncol
; 7(6): 869-877, 2021 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33983395
5.
Combined analysis of IGHV mutations, telomere length and CD49d identifies long-term progression-free survivors in TP53 wild-type CLL treated with FCR-based therapies.
Leukemia
; 36(1): 271-274, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34148055